Compare ADMA Biologics Inc (ADMA) vs Alphabet Inc Class A (GOOGL) Price & Performance

ADMA Biologics IncTrade

Alphabet Inc Class ATrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Alphabet Inc Class A — how do they compare? ADMA Biologics Inc trades at $9.95 (market cap $2.22B), while Alphabet Inc Class A trades at $342.06 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 1891.9× ADMA Biologics Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

	ADMA	GOOGL
Market Cap	$2.22B	$4.20T
Sector	Health	Media
52-Week High	$20.38	$402.62
52-Week Low	$7.60	$199.32
Enterprise Value	$2.29B	$4.09T
Dividend Yield	—	0.26%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

Alphabet Inc Class A

Alphabet (GOOGL) trades at $357.52, up 0.91% today, with a bullish technical signal from moving averages and strong support at $354. The stock shows robust fundamentals, with revenue growing from $350.0B in 2024 to $402.8B in 2025 (SEC filings, 2025), net income margin expanding to 32.8%, and consistent earnings beats. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube price increases (Reuters, 2026-04-10).

Outlook remains positive with an 85% analyst buy rating and $426.28 consensus price target (MarketBeat, 2026-04-11), though risks include antitrust scrutiny and tech sector volatility. Earnings growth and AI integration are key catalysts for upside, while competition and regulatory pressures warrant monitoring.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ADMA

Investigation launched into ADMA Biologics for alleged channel-stuffing to boost ASCENIV sales.Newsfile Corp · 6 hours agoBearish View details →

GOOGL

Google unveils Pixel 11 series, Pixel Watch 5, and Pixel Tag tracker with new AI features.TechCrunch · 5 hours agoBullish Google's Quick Share adds tap-to-share mode for faster Android device sharingTechCrunch · 5 hours agoBullish Google launches Pixel Watch 5 with advanced health tracking and smarter AI features starting at $399TechCrunch · 5 hours agoBullish View details →

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

About Alphabet Inc Class A

Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.